PLK4作为增强三阴性乳腺癌放射敏感性的潜在靶点
本研究在三阴性乳腺癌(TNBC)细胞系与患者来源类器官(PDO)中,探讨抑制极光样激酶4(PLK4)联合放疗的抗增殖作用及机制;CFI-400945、Centrinone B或siRNA下调PLK4联合放疗较未处理或单药处理显著增强抗增殖效果,PDO中观察到协同作用,中心粒过度扩增可能参与该联合作用。
要点
- CFI-400945、Centrinone B抑制PLK4或siRNA下调PLK4联合放疗,较未处理或单药处理显著增强TNBC细胞系与PDO的抗增殖效果。
- 在PDO中采用反应矩阵观察到CFI-400945与放疗的抗癌协同作用。
- 中心粒过度扩增可能参与放疗与PLK4抑制的联合抗增殖作用。
核心结论
- 数据提示PLK4是增强TNBC放疗抗癌效果的有前景靶点,该作用至少部分由中心粒过度扩增所介导。
- 结果支持进一步开展抗PLK4药物与放疗联合抗癌策略的机制与转化研究。
研究设计与样本
- 在TNBC细胞系与患者来源类器官(PDO)中采用集落形成实验评估治疗后的细胞增殖。
- 在TNBC细胞系中用siRNA沉默下调PLK4表达,并用针对centrin的免疫荧光评估中心粒扩增变化。
主要发现
- CFI-400945或Centrinone B抑制PLK4、或siRNA下调PLK4,与放疗联合时较未处理或单处理细胞在TNBC细胞系与PDO中抗增殖效果显著增加。
- 在PDO中用反应矩阵观察到CFI-400945与放疗的抗癌协同作用。
- 中心粒过度扩增可能参与放疗与PLK4抑制的联合抗增殖作用。
局限性
- 原文结论提出这些结果支持进一步开展抗PLK4药物与放疗联合的机制与转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioresistance is one of the barriers to developing more effective therapies against the most aggressive, triple-negative, breast cancer (TNBC) subtype. In our previous studies, we showed that inhibition of Polo-like Kinase 4 (PLK4) by a novel drug, CFI-400945 significantly enhances the anticancer effects of radiotherapy (RT) compared to single treatment alone. Here we further investigate the role of PLK4 in enhancing radiation effects in TNBC and explore mechanisms of PLK4 inhibition and radiation combinatorial antiproliferative effects. To assess cellular proliferation in response to treatments, we used colony formation assays in TNBC cell lines and patient-derived organoids (PDOs). Downregulation of PLK4 expression was achieved using siRNA silencing in TNBC cell lines. Immunofluorescence against centrin was used to assess the alteration of centriole amplification in response to treatments. We observed that inhibition of PLK4 by CFI-400945 or Centrinone B or its downregulation by siRNA, when combined with RT, resulted in a significant increase in antiproliferative effect in TNBC cells lines and PDOs compared to untreated or single-treated cells. Anticancer synergy was observed using a response matrix in PDOs treated with CFI-400945 and RT. We show that the overamplification of centrioles might be involved in the combined antiproliferative action of RT and PLK4 inhibition. Our data suggest that PLK4 is a promising target for enhancing the anticancer effects of RT in TNBC that, at least in part, is modulated by the overamplification of centrioles. These results support further mechanistic and translational studies of anti-PLK4 agents and RT as an anticancer combination treatment strategy.
引用
- Pellizzari S, Bhat V, Athwal H, et al. PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer. Radiat Oncol. 2024. PMID: 38365710. doi:10.1186/s13014-024-02410-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。